|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPATCH2 |
Gene summary for GPATCH2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPATCH2 | Gene ID | 55105 |
| Gene name | G-patch domain containing 2 | |
| Gene Alias | CT110 | |
| Cytomap | 1q41 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NW75 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55105 | GPATCH2 | CCI_1 | Human | Cervix | CC | 1.77e-04 | 7.31e-01 | 0.528 |
| 55105 | GPATCH2 | CCI_2 | Human | Cervix | CC | 6.18e-05 | 6.87e-01 | 0.5249 |
| 55105 | GPATCH2 | CCI_3 | Human | Cervix | CC | 4.94e-10 | 9.19e-01 | 0.516 |
| 55105 | GPATCH2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.03e-10 | -5.15e-01 | 0.0155 |
| 55105 | GPATCH2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 8.27e-03 | -4.67e-01 | -0.1207 |
| 55105 | GPATCH2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.09e-09 | -5.15e-01 | 0.096 |
| 55105 | GPATCH2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.52e-05 | -3.80e-01 | 0.0674 |
| 55105 | GPATCH2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.89e-09 | -3.23e-01 | 0.294 |
| 55105 | GPATCH2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.56e-11 | -4.67e-01 | 0.3005 |
| 55105 | GPATCH2 | A001-C-207 | Human | Colorectum | FAP | 1.16e-02 | -3.24e-01 | 0.1278 |
| 55105 | GPATCH2 | A015-C-203 | Human | Colorectum | FAP | 2.41e-21 | -3.04e-01 | -0.1294 |
| 55105 | GPATCH2 | A015-C-204 | Human | Colorectum | FAP | 3.89e-03 | -1.30e-01 | -0.0228 |
| 55105 | GPATCH2 | A014-C-040 | Human | Colorectum | FAP | 1.13e-02 | -3.93e-01 | -0.1184 |
| 55105 | GPATCH2 | A002-C-201 | Human | Colorectum | FAP | 4.60e-06 | -2.08e-01 | 0.0324 |
| 55105 | GPATCH2 | A002-C-203 | Human | Colorectum | FAP | 4.13e-03 | -1.67e-01 | 0.2786 |
| 55105 | GPATCH2 | A001-C-119 | Human | Colorectum | FAP | 3.94e-04 | -3.65e-01 | -0.1557 |
| 55105 | GPATCH2 | A001-C-108 | Human | Colorectum | FAP | 1.12e-10 | -1.71e-01 | -0.0272 |
| 55105 | GPATCH2 | A002-C-205 | Human | Colorectum | FAP | 1.03e-16 | -2.73e-01 | -0.1236 |
| 55105 | GPATCH2 | A015-C-005 | Human | Colorectum | FAP | 4.08e-02 | -1.71e-01 | -0.0336 |
| 55105 | GPATCH2 | A015-C-006 | Human | Colorectum | FAP | 2.44e-08 | -2.32e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPATCH2 | SNV | Missense_Mutation | novel | c.1045N>A | p.His349Asn | p.H349N | Q9NW75 | protein_coding | tolerated(0.56) | benign(0.075) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| GPATCH2 | SNV | Missense_Mutation | novel | c.1484N>G | p.Glu495Gly | p.E495G | Q9NW75 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GPATCH2 | SNV | Missense_Mutation | rs757315065 | c.475N>T | p.Arg159Cys | p.R159C | Q9NW75 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GPATCH2 | SNV | Missense_Mutation | c.772A>C | p.Ser258Arg | p.S258R | Q9NW75 | protein_coding | tolerated(0.06) | probably_damaging(0.972) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GPATCH2 | SNV | Missense_Mutation | rs375962510 | c.217C>T | p.Arg73Trp | p.R73W | Q9NW75 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GPATCH2 | SNV | Missense_Mutation | c.164G>A | p.Arg55Gln | p.R55Q | Q9NW75 | protein_coding | tolerated(0.37) | possibly_damaging(0.836) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GPATCH2 | SNV | Missense_Mutation | novel | c.974N>G | p.Ile325Ser | p.I325S | Q9NW75 | protein_coding | tolerated(0.07) | probably_damaging(0.996) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GPATCH2 | SNV | Missense_Mutation | rs375962510 | c.217N>T | p.Arg73Trp | p.R73W | Q9NW75 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GPATCH2 | SNV | Missense_Mutation | novel | c.496C>T | p.Arg166Cys | p.R166C | Q9NW75 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| GPATCH2 | SNV | Missense_Mutation | rs150988724 | c.476N>A | p.Arg159His | p.R159H | Q9NW75 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FI-A2D6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |